Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

rate ("CER") basis, which is a Non GAAP measure, product sales were up 25%.

Product sales in the quarter benefited from higher ADDERALL XR® sales, in part due to significantly lower sales deductions following a lowering of the estimate of inventory in the US retail pipeline.

  • The strong product sales growth more than offset declines in 3TC® and ZEFFIX® royalties, both of which are now affected by the disagreement with GlaxoSmithKline ("GSK"), to give growth in total revenues of 24%, to $1,086 million in the quarter (Q3 2010: $874 million).


 

  • As expected, research and development ("R&D") was up 21% on a Non GAAP basis compared to Q3 2010, as we continue to invest in both early and late stage programs across our business to enable us to deliver future growth. On a US GAAP basis, R&D expenditure increased 2% compared to Q3 2010.


 

  • Non GAAP operating income was up 15% to $341 million (Q3 2010: $298 million). As expected, Non GAAP operating expenses increased at broadly the same rate as the increase in product sales compared to Q3 2010. This increase was due to increased investment in our R&D program and higher selling, general and administrative ("SG&A") expenditure as we absorb the operating costs of Advanced BioHealing Inc. ("ABH") and Movetis, neither of which were incurred in Q3 2010, in addition to supporting product launches and our continued growth.


 

Non GAAP diluted earnings per American Depositary Share ("ADS") were up 10% to $1.28 (Q3 2010: $1.16), due to the higher Non GAAP operating income, partially offset by higher Non GAAP Other Expenses.

  • On a US GAAP basis, operating income was up 64% to $255 million (Q3 2010: $156 million). Q3
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 30, 2014 Two ... America were hosted by Charm Sciences at its ... their week in the US, the participants discussed ... control, hygiene management, and process verification, and received ... , This was the first visit to the ...
(Date:10/31/2014)... October 31, 2014 Following the successful ... free learning webinar to introduce its new product and ... and biostatisticians. , Launched in September, Formedix On Demand ... of clinical trial automation tools. For the first time, ... browser. And by introducing Formations – a revolutionary new ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
... Work" Around the World, RESEARCH TRIANGLE PARK, N.C., Sept. ... Work(R) (GPTW) Institute as one of,the top 100 "Best Companies ... by the weekly news magazine Epoca, one of the most,widely ... was also named to the GPTW Institute,s,"Best Workplace" rankings in ...
... BioTrends Research Group, Inc. is,pleased to announce the ... in a series conducted with Anemia Managers. It is,based ... 150 Anemia Managers,-- 100 working with dialysis patients and ... and qualitative interviews with a,subset of 25 respondents. The ...
... facet ... WALTHAM, Mass., Sept. 11 According to Millennium,Research ... report, the facet fixation market, which includes facet screws, ... growth rate of over,60% from 2007 to 2012. This ...
Cached Biology Technology:Quintiles Recognized Among 'Best Companies to Work For' in Brazil 2New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 2New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 3US Facet Fixation Market to Increase by Over 60% Annually Through 2012 2US Facet Fixation Market to Increase by Over 60% Annually Through 2012 3
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... the largest study of its kind to date, researchers ... that heighten the risk for autism. Joseph Buxbaum, Ph.D., ... City, Mark Daly, Ph.D., Broad Institute of Harvard and ... samples from affected children, parents and unrelated people. They ... contribute to the risk for autism spectrum disorder (ASD) ...
(Date:10/29/2014)... both genetic and environmental, have been blamed for ... Some, such as a family history of schizophrenia, ... Toxoplasma gondii , a parasite transmitted by ... viewed with skepticism. , A new study by ... at the University of Pennsylvania,s School of Veterinary ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... deadlines loom for manufacturers of chemicals for products ranging ... Philadelphia will bring together scientists, cosmetics formulators, and policy ... of the Cosmetics Directive, a series of deadlines for ... massive undertaking to identify potential hazards from thousands of ...
... plastic limbs and metal rods to complex virtual humans made ... yesteryear are evolving and researchers at Wake Forest University School ... This new generation of human body models will represent ... "dummies" before. The models will contain detailed representation of the ...
... Two teams of scientists from Harvard-MIT Division of ... Women,s Hospital have developed a new self-assembling hydrogel ... drug release, and easy to tailor. Importantly, these ... concentrations without requiring carriers for the drug or ...
Cached Biology News:Spotlight on cosmetic ingredients conference 2Wake Forest plays integral role in effort to revolutionize vehicle safety 2Wake Forest plays integral role in effort to revolutionize vehicle safety 3